Literature DB >> 23372165

Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria.

Lucia Gargiulo1, Maria Papaioannou, Michela Sica, Giulia Talini, Aristeidis Chaidos, Barbara Richichi, Andrei V Nikolaev, Cristina Nativi, Mark Layton, Josu de la Fuente, Irene Roberts, Lucio Luzzatto, Rosario Notaro, Anastasios Karadimitris.   

Abstract

The mechanism of bone marrow failure (BMF) in paroxysmal nocturnal hemoglobinuria (PNH) is not yet known. Because in PNH the biosynthesis of the glycolipid molecule glycosylphosphatidylinositol (GPI) is disrupted in hematopoietic stem and progenitor cells by a somatic mutation in the PIG-A gene, BMF might result from an autoimmune attack, whereby T cells target GPI in normal cells, whereas PIG-A mutant GPI-negative cells are spared. In a deliberate test of this hypothesis, we have demonstrated in PNH patients the presence of CD8(+) T cells reactive against antigen-presenting cells (APCs) loaded with GPI. These T cells were significantly more abundant in PNH patients than in healthy controls; their reactivity depended on CD1d expression and they increased upon coculture with CD1d-expressing, GPI-positive APCs. In GPI-specific T cells captured by CD1d dimer technology, we identified, through global T-cell receptor α (TCRα) analysis, an invariant TCRVα21 sequence, which was then found at frequencies higher than background in the TCR repertoire of 6 of 11 PNH patients. Thus, a novel, autoreactive, CD1d-restricted, GPI-specific T-cell population, enriched in an invariant TCRα chain, is expanded in PNH patients and may be responsible for BMF in PNH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23372165     DOI: 10.1182/blood-2012-11-469353

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  Clonal hematopoiesis.

Authors:  Max Jan; Benjamin L Ebert; Siddhartha Jaiswal
Journal:  Semin Hematol       Date:  2016-10-20       Impact factor: 3.851

2.  T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways.

Authors:  Kohei Hosokawa; Sachiko Kajigaya; Keyvan Keyvanfar; Wangmin Qiao; Yanling Xie; Danielle M Townsley; Xingmin Feng; Neal S Young
Journal:  J Immunol       Date:  2017-06-19       Impact factor: 5.422

Review 3.  Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-07       Impact factor: 3.722

Review 4.  Inflammatory bone marrow microenvironment.

Authors:  Nils B Leimkühler; Rebekka K Schneider
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  Clinical significance of acquired somatic mutations in aplastic anaemia.

Authors:  J C W Marsh; G J Mufti
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

Review 6.  Paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

Review 7.  Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; Antonio M Risitano; John D Lambris
Journal:  Semin Hematol       Date:  2018-02-14       Impact factor: 3.851

Review 8.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

Review 9.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.

Authors:  Robert L Bowman; Lambert Busque; Ross L Levine
Journal:  Cell Stem Cell       Date:  2018-02-01       Impact factor: 24.633

10.  Paroxysmal nocturnal hemoglobinuria with copy number-neutral 6pLOH in GPI (+) but not in GPI (-) granulocytes.

Authors:  Yasutaka Ueda; Jun-ichi Nishimura; Yoshiko Murakami; Sachiko Kajigaya; Taroh Kinoshita; Yuzuru Kanakura; Neal S Young
Journal:  Eur J Haematol       Date:  2014-01-30       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.